In addition, several GM‐CSF inhibitors, including otilimab, gimsilumab, and TJ003234, are under evaluation in clinical trials for COVID‐19 (NCT04351243, NCT04376684, NCT04341116). The gene discussed is CSF2; the disease is COVID-19.